JHW 007 hydrochlorideHigh affinity dopamine uptake inhibitor CAS# 202645-74-7 |
- Cyclopamine
Catalog No.:BCN2964
CAS No.:4449-51-8
- Purmorphamine
Catalog No.:BCC3641
CAS No.:483367-10-8
- GANT61
Catalog No.:BCC1090
CAS No.:500579-04-4
- GANT 58
Catalog No.:BCC1587
CAS No.:64048-12-0
- GDC-0449 (Vismodegib)
Catalog No.:BCC1285
CAS No.:879085-55-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 202645-74-7 | SDF | Download SDF |
PubChem ID | 71771746 | Appearance | Powder |
Formula | C24H30ClF2NO | M.Wt | 421.95 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
Chemical Name | (1S,5R)-3-[bis(4-fluorophenyl)methoxy]-8-butyl-8-azabicyclo[3.2.1]octane;hydrochloride | ||
SMILES | CCCCN1C2CCC1CC(C2)OC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl | ||
Standard InChIKey | RHYMGBAYGRUKNZ-DHWZJIOFSA-N | ||
Standard InChI | InChI=1S/C24H29F2NO.ClH/c1-2-3-14-27-21-12-13-22(27)16-23(15-21)28-24(17-4-8-19(25)9-5-17)18-6-10-20(26)11-7-18;/h4-11,21-24H,2-3,12-16H2,1H3;1H/t21-,22+,23?; | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Dopamine uptake inhibitor; displays high affinity for the dopamine transporter (DAT) (Ki = 25 nM compared to 1330 and 1730 for NET and SERT respectively). Suppresses the effects of cocaine administration in a dose-dependent manner and decreases cocaine and methamphetamine self-administration in rats. |
JHW 007 hydrochloride Dilution Calculator
JHW 007 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3699 mL | 11.8497 mL | 23.6995 mL | 47.399 mL | 59.2487 mL |
5 mM | 0.474 mL | 2.3699 mL | 4.7399 mL | 9.4798 mL | 11.8497 mL |
10 mM | 0.237 mL | 1.185 mL | 2.3699 mL | 4.7399 mL | 5.9249 mL |
50 mM | 0.0474 mL | 0.237 mL | 0.474 mL | 0.948 mL | 1.185 mL |
100 mM | 0.0237 mL | 0.1185 mL | 0.237 mL | 0.474 mL | 0.5925 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- DL-AP4
Catalog No.:BCC6548
CAS No.:20263-07-4
- DL-AP3
Catalog No.:BCC2459
CAS No.:20263-06-3
- Ginkgolic acid C13:0
Catalog No.:BCN5333
CAS No.:20261-38-5
- H-Valinol
Catalog No.:BCC2696
CAS No.:2026-48-4
- Calyxin H
Catalog No.:BCN4888
CAS No.:202596-22-3
- OTX-015
Catalog No.:BCC1829
CAS No.:202590-98-5
- 13-O-Ethylpiptocarphol
Catalog No.:BCN7448
CAS No.:202522-40-5
- 13(18)-Oleanen-3-one
Catalog No.:BCN4887
CAS No.:20248-08-2
- JANEX-1
Catalog No.:BCC1668
CAS No.:202475-60-3
- Glomeratose A
Catalog No.:BCN8400
CAS No.:202471-84-9
- Ro 04-6790
Catalog No.:BCC7512
CAS No.:202466-68-0
- AM 281
Catalog No.:BCC6944
CAS No.:202463-68-1
- 3α-Bis-(4-fluorophenyl) methoxytropane hydrochloride
Catalog No.:BCC6846
CAS No.:202646-03-5
- Nicotinamide N-oxide
Catalog No.:BCN1969
CAS No.:1986-81-8
- Forsythenside A
Catalog No.:BCN6440
CAS No.:202721-09-3
- Homodihydrocapsaicin I
Catalog No.:BCN7844
CAS No.:20279-06-5
- 4-Methoxycoumarine
Catalog No.:BCN6536
CAS No.:20280-81-3
- Orexin B (mouse)
Catalog No.:BCC5766
CAS No.:202801-92-1
- Licoagrochalcone A
Catalog No.:BCC8197
CAS No.:202815-28-9
- BMS 191011
Catalog No.:BCC7448
CAS No.:202821-81-6
- Ralfinamide mesylate
Catalog No.:BCC7844
CAS No.:202825-45-4
- Safinamide Mesylate
Catalog No.:BCC2320
CAS No.:202825-46-5
- Rosmarinic acid
Catalog No.:BCN5893
CAS No.:20283-92-5
- 8-Hydroxy-3,5,7,3',4',5'-hexamethoxyflavone
Catalog No.:BCN1506
CAS No.:202846-95-5
Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats.[Pubmed:24194527]
J Pharmacol Exp Ther. 2014 Jan;348(1):174-91.
Atypical dopamine-uptake inhibitors have low abuse potential and may serve as leads for development of cocaine-abuse treatments. Among them, the benztropine (BZT) derivatives, N-butyl (JHW007), N-allyl (AHN2-005), and N-methyl (AHN1-055) analogs of 3alpha-[bis(4'-fluorophenyl)methoxy]-tropane dose-dependently decreased cocaine self-administration without effects on food-maintained responding. Our study examined selectivity by assessing their effects on self-administration of other drugs. As with cocaine, each BZT analog (1.0-10.0 mg/kg i.p.) dose-dependently decreased maximal self-administration of d-methamphetamine (0.01-0.32 mg/kg/infusion) but was inactive against heroin (1.0-32.0 microg/kg/infusion) and ketamine (0.032-1.0 mg/kg/infusion) self-administration. Further, standard dopamine indirect-agonists [WIN35,428 ((-)-3beta-(4-fluorophenyl)-tropan-2-beta-carboxylic acid methyl ester tartrate), d-amphetamine (0.1-1.0 mg/kg i.p., each)] dose-dependently left-shifted self-administration dose-effect curves for d-methamphetamine, heroin, and ketamine. Noncompetitive NMDA-glutamate receptor/channel antagonists [(+)-MK-801 (0.01-0.1 mg/kg i.p.), memantine (1.0-10.0 mg/kg i.p.)] also left-shifted dose-effect curves for d-methamphetamine and ketamine (but not heroin) self-administration. The micro-agonists [dl-methadone and morphine (1.0-10.0 mg/kg i.p., each)] dose-dependently decreased maximal self-administration of micro-agonists (heroin, remifentanil) but not d-methamphetamine or ketamine self-administration. The micro-agonist-induced decreases were similar to the effects of BZT analogs on stimulant self-administration and effects of food prefeeding on responding maintained by food reinforcement. Radioligand-binding and behavioral studies suggested that inhibition of dopamine transporters and sigma receptors were critical for blocking stimulant self-administration by BZT-analogs. Thus, the present results suggest that the effects of BZT analogs on stimulant self-administration are similar to effects of micro-agonists on micro-agonist self-administration and food prefeeding on food-reinforced responding, which implicates behavioral mechanisms for these effects and further supports development of atypical dopamine uptake inhibitors as medications for stimulant abuse.
Dopamine transporter-dependent and -independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability.[Pubmed:20855444]
J Pharmacol Exp Ther. 2010 Dec;335(3):703-14.
The benztropine analog N-(n-butyl)-3alpha-[bis(4'-fluorophenyl)methoxy]-tropane (JHW 007) displays high affinity for the dopamine transporter (DAT), but unlike typical DAT ligands, has relatively low abuse liability and blocks the effects of cocaine, including its self-administration. To determine sites responsible for the cocaine antagonist effects of JHW 007, its in vitro binding was compared with that of methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate (WIN 35428) in rats, mice, and human DAT (hDAT)-transfected cells. A one-site model, with K(d) values of 4.21 (rat) and 8.99 nM (mouse) best fit the [(3)H]WIN 35428 data. [(3)H]JHW 007 binding best fit a two-site model (rat, 7.40/4400 nM; mouse, 8.18/2750 nM), although a one-site fit was observed with hDAT membranes (43.7 nM). Drugs selective for the norepinephrine and serotonin transporters had relatively low affinity in competition with [(3)H]JHW 007 binding, as did drugs selective for other sites identified previously as potential JHW 007 binding sites. The association of [(3)H]WIN 35428 best fit a one-phase model, whereas the association of [(3)H]JHW 007 best fit a two-phase model in all tissues. Because cocaine antagonist effects of JHW 007 have been observed previously soon after injection, its rapid association observed here may contribute to those effects. Multiple [(3)H]JHW 007 binding sites were obtained in tissue from mice lacking the DAT, suggesting these as yet unidentified sites as potential contributors to the cocaine antagonist effects of JHW 007. Unlike WIN 35428, the binding of JHW 007 was Na(+)-independent. This feature of JHW 007 has been linked to the conformational status of the DAT, which in turn may contribute to the antagonism of cocaine.
The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization.[Pubmed:20413276]
Eur Neuropsychopharmacol. 2010 Jul;20(7):501-8.
The discovery and evaluation of high affinity dopamine transport inhibitors with low abuse liability is an important step toward the development of efficacious medications for cocaine addiction. We examined in mice the behavioural effects of (N-(n-butyl)-3alpha-[bis(4'-fluorophenyl)methoxy]-tropane) (JHW 007), a benztropine (BZT) analogue that blocks dopamine uptake, and assessed its potential to influence the actions of cocaine in clinically-relevant models of cocaine addiction. In the conditioned place preference (CPP) paradigm, JHW 007 exposure did not produce place conditioning within an ample dose range but effectively blocked the CPP induced by cocaine administration. Similarly, in the CPP apparatus JHW 007 treatment failed to stimulate locomotor activity at any dose but dose-dependently suppressed the hyperactivity evoked by cocaine treatment. In locomotor sensitization assays performed in the open field, JHW 007 did not produce sensitized locomotor behaviour when given alone, but it prevented the sensitized component of the locomotor response elicited by subchronic (8-day) cocaine exposure. In the elevated plus maze (EPM), acute treatment with JHW 007, cocaine and combinations of the BZT analogue and cocaine produced an anxiogenic-like profile. Re-test in the EPM following subchronic (8-day) exposure enhanced the anxiogenic-like effect of the same drug treatments. The present findings indicate that JHW 007 exposure counteracts some critical behavioural correlates of cocaine treatment, including conditioned reward, locomotor stimulation and sensitization, and lend support to the further development of BZT analogues as potential replacement medications in cocaine addiction.